Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Homology Medicines Inc (FIXX) USD0.0001

Sell:$8.02 Buy:$8.88 Change: $0.58 (7.34%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$8.02
Buy:$8.88
Change: $0.58 (7.34%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$8.02
Buy:$8.88
Change: $0.58 (7.34%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.

Contact details

Address:
1 Patriots Park
BEDFORD
01730-2343
United States
Telephone:
+1 (781) 3017277
Website:
https://www.homologymedicines.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FIXX
ISIN:
US4380831077
Market cap:
$451.00 million
Shares in issue:
57.09 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Arthur Tzianabos
    President, Chief Executive Officer, Director
  • W. Bradford Smith
    Chief Financial Officer, Treasurer, Secretary
  • Tim Kelly
    Chief Operating Officer
  • Albert Seymour
    Chief Scientific Officer
  • Gabriel Cohn
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.